pepdex
← Back to index
055

PNC-27

Membranolytic peptide that selectively kills cancer cells expressing HDM-2 (oncoprotein) on the membrane surface. Pre-clinical anti-cancer research compound.

Immune
Evidence: Anecdotal
Half-life
~hours
Route
Subcutaneous or IV (research)
Cycle
Highly variable per protocol
Schedule
Daily in research protocols
In plain English

PNC-27 is a peptide that punches holes in cancer-cell membranes by binding HDM-2, an oncoprotein found on tumor cell surfaces. Healthy cells don't express HDM-2 on the surface, so it's selective in theory. Pre-clinical research compound — not approved for treatment.

Status & legality
Natty?
Grey area

Anti-cancer peptide. Federations don't typically address research compounds.

FDA
Not approved

Not FDA approved. Pre-clinical research compound.

Compounding
Not classified

Not formally categorized in the FDA bulks lists.

WADA
Not listed
Prescribed

Not prescribed in conventional medicine outside research contexts.

Who it's for

  • Cancer-research contexts under medical oversight
  • Educational reference — pre-clinical only
  • Compassionate-use research scenarios

What to expect

  1. Week 1

    Acute responses in animal/cell models.

  2. Week 4

    Pre-clinical endpoint.

  3. Week 8

    No human long-term safety data.

How it works (mechanism)

Membranolytic peptide. Selectively binds HDM-2 (an oncoprotein) found on the membrane surface of cancer cells (rarely on healthy cells), then lyses the cell membrane. Pre-clinical anti-cancer mechanism.

Dosing protocol

No standardized human dose. Pre-clinical models use per-kg dosing.

Stacks well with

Standalone in research contexts

Side effects

01Limited human safety data
02Theoretical off-target membrane effects
03Injection-site reaction

When NOT to use

  • Anyone without medical oversight
  • Pregnancy / nursing
  • Active autoimmune conditions

Bloodwork to monitor

  • CBC, CMP, LFTs at minimum if researching

Common mistakes

  • Self-administering for cancer treatment (this is pre-clinical, not approved)
  • Skipping medical oversight
  • Long cycles without safety monitoring

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is PNC-27?+
PNC-27 is a peptide that punches holes in cancer-cell membranes by binding HDM-2, an oncoprotein found on tumor cell surfaces. Healthy cells don't express HDM-2 on the surface, so it's selective in theory. Pre-clinical research compound — not approved for treatment.
Is PNC-27 FDA approved?+
Not FDA approved. Pre-clinical research compound.
Is PNC-27 banned by WADA?+
PNC-27 is not currently on the WADA prohibited list.
Are you still natty after taking PNC-27?+
Grey area. Anti-cancer peptide. Federations don't typically address research compounds.
Do doctors prescribe PNC-27?+
Not prescribed in conventional medicine outside research contexts.
What's the typical dose of PNC-27?+
No standardized human dose. Pre-clinical models use per-kg dosing.
What are the side effects of PNC-27?+
Common side effects include: Limited human safety data; Theoretical off-target membrane effects; Injection-site reaction. Less common effects and full safety details are on the entry page.
How long until PNC-27 starts working?+
Acute responses in animal/cell models.